1. Mega Biotech: Risk per Option Market - 1 $VRTX 2 $ILMN 5 $BIIB 7 $REGN Do It Yourself --> http://lite.capitalmarketlabs.com/cmld3b/xy.php?sector=Pharmaceuticals,+Biotechnology+and+Life+Sciences|&x=Equal+Spaced&y=30-Day+Implied+Volatility&minMarketCap=24998&maxMarketCap=1000000&minRevenue=0&maxRevenue=1000000

  2. $BIIB vs. $REGN vs. $AMGN vs. $CELG Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=BIIB|REGN|AMGN|CELG|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  3. $celg $biib $cytx $nlnk $REGN $oncy $vblt ok traders, who s gonna pounce on XBIO on ipo day?

  4. $BIIB vs. $ALXN vs. $REGN vs. $GILD Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=BIIB|ALXN|REGN|GILD|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  5. $REGN vs. $ALXN vs. $AMGN vs. $PCYC Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=REGN|ALXN|AMGN|PCYC|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  6. $REGN vs. $ALXN vs. $GILD vs. $AMGN Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=REGN|ALXN|GILD|AMGN|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  7. $REGN Assets are Increasing. Chart: http://lite.capitalmarketlabs.com/cmld3b/index.php?shortcode=REGN&financial_bar=Assets+(US$+Millions)&financial_line=Assets+(US$+Millions)&start_date=03/31/2000&end_date=12/31/2014&show_line=false&sk=e1d1d71a00571b33c4b346eaeeb65430

  8. $ALXN vs. $REGN vs. $GILD vs. $PCYC Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=ALXN|REGN|GILD|PCYC|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  9. @OphirGottlieb Biotech/Pharma: Revenue per Employee - 1 $GILD 2 $BIIB 3 $CELG 4 $PCYC 7 $REGN Chart -> http://lite.capitalmarketlabs.com/cmld3b/xy.php?sector=Pharmaceuticals,+Biotechnology+and+Life+Sciences|&x=Equal+Spaced&y=Revenue/Number+of+Employees+(TTM+US$+Millions)&minMarketCap=15000&maxMarketCap=1000000&minRevenue=0&maxRevenue=1000000 absurd.

  10. Biotech/Pharma: Revenue per Employee - 1 $GILD 2 $BIIB 3 $CELG 4 $PCYC 7 $REGN Chart -> http://lite.capitalmarketlabs.com/cmld3b/xy.php?sector=Pharmaceuticals,+Biotechnology+and+Life+Sciences|&x=Equal+Spaced&y=Revenue/Number+of+Employees+(TTM+US$+Millions)&minMarketCap=15000&maxMarketCap=1000000&minRevenue=0&maxRevenue=1000000

  11. MACD Bearish http://www.dailystockplays.com/MACD-Bearish-2015-03-27.html $REGN $AMGN $BAYRY $SLG $IJS $CLX $IXJ $ARE $ESPR $ROG $UA $IOO $NSRGY $FIS $MYL $ACWI $TMH $TPX $AFSI

  12. $REGN 15 mins.. can we close a $460...next week looks good so far..

  13. @OphirGottlieb: $BIIB vs. $GILD vs. $REGN vs. $AMGN Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=BIIB|GILD|REGN|AMGN|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  14. $BIIB vs. $GILD vs. $REGN vs. $AMGN Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=BIIB|GILD|REGN|AMGN|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  15. One of the bigger recent insider buys was yesterday s $183,342 purchase of $REGN, according to this list http://www.conferencecalltranscripts.org/insider/

  16. $REGN - Regeneron price target raised to $500 from $450 at Argus

  17. #fastfoodnation for the win! $ICPT #wouldyoulikefrieswiththat $IBB $BIB $REGN $MNKD

  18. $REGN expecting another shot at $460 today if that breaks then $465 pin possible today

  19. Someone please answer: If biotech isn t a bubble, what is? $IBB $JUNO $KITE $BLUE $BIIB $GILD $REGN $CELG $ISIS $ABBV $ESPR $ICPT $ABBV

  20. Eyes Catching Stocks- $KRFT $F $REGN http://www.streetwisereport.com/eyes-catching-stocks-kraft-foods-group-inc-nasdaqkrft-ford-motor-co-nysef-regeneron-pharmaceuticals-inc-nasdaqregn/113012/

  21. If you are regretting getting shaken out of $IBB $ISIS $JUNO $REGN, consider some due diligence on $BLCM.

  22. $PMCB $HEB $IBIO $OREGN X $OHRP $BMRN $BIIB $REGN $CELG $GILD http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/

  23. $BIIB $REGN yes gentlemen!the power of the first pullback.whatever happened to the bubble?keep waiting for it to burst :)

  24. Robert Freedland holds an allocation of 4.6% in $REGN in his Healthcare Investment Portfolio

  25. $CELG vs. $ALXN vs. $BIIB vs. $REGN Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=CELG|ALXN|BIIB|REGN|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)